NRXS Stock Forecast: NeurAxis, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$4.22
−6.22% on the day

The median 12-month analyst price target for NeurAxis, Inc. is $11. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 47 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$63.9M
Ticker Nerd rank
47/ 100
Median analyst target
$11
Analysts covering
2
Revenue$1.9M+115.7% y/y
Operating income−$2.1M
Net income−$2.1M
Free cash flow−$1.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−22.1%
1M
−46.0%
YTD
−7.0%
1Y
+68.1%
From 52W high
−52.1%
From 52W low
+68.1%
$2.51
$8.81
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores NeurAxis, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
47/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
84
Accruals
62
Volatility
50
Quality
46
Growth
45
Issuance
39
Value
32
Revisions
31

Momentum (84): The shares have been drifting up relative to others.

Revisions (31): Analysts have, on balance, been cutting their forecasts.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

NRXS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NRXS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$4.00$6.00$8.00$10.00$12.00$14.00Jan 26Apr 26Jul 26Oct 26NRXSHigh $13Median $11Low $9

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
2
Buy
0
Hold
0
Sell
$9
Low
$11
Median
$13
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
20 Mar 2026Craig-HallumMaintainsBuy—
22 Dec 2025Craig-HallumMaintainsBuy—
16 June 2025Craig-HallumInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for NRXS.

Market Radar

This page is one stock. Monday covers all of them.

NRXS appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

NRXS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, NeurAxis, Inc. returned +68.1% against +6.9% for the S&P 500, dividends included.

NRXS vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250300350Jan 26Apr 26Jul 26Oct 26NRXSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

NRXS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
9.8×

Cheaper than 12% of US stocks

Price / book
17.2×

Cheaper than 4% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
85.9%

Higher than 94% of US stocks

Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−409.7%

Higher than 3% of US stocks

Return on assets
−122.3%

Higher than 2% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • NeurAxis, Inc. has a market value of $63.9M and an enterprise value of $59.8M.

  • Revenue in the twelve months to 30 June 2026: $5.3M. The latest quarter grew 115.7% year on year.

  • Net income over the same four quarters: −$7.7M, a −144.4% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$5.7M.

  • Shares outstanding: 12.5M.

  • NeurAxis, Inc. employs 24 people — $222K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

NRXS and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
NRXSNeurAxis, Inc.$63.9M47
TENXTenax Therapeutics, Inc.$56.9M24
NTRBNutriband, Inc.$59.8M33
CSBRChampions Oncology, Inc.$59.8M27
IBIOiBio, Inc.$56.4M32
NMRANeumora Therapeutics, Inc.$60.8M35
VTVTvTv Therapeutics, Inc.$61.1M69

Take a look at NRXS’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own NeurAxis, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about NRXS

What is the NRXS stock price forecast for 2026-2027?

The median 12-month analyst price target for NeurAxis, Inc. is $11, with estimates ranging from $9 to $13. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NRXS stock a buy right now?

Of the 2 analysts covering NeurAxis, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks NeurAxis, Inc. 47 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NRXS?

As at 21 Nov 2026, NeurAxis, Inc. ranks 47 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (84 of 100).

Will NRXS stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts is $11, and Ticker Nerd's factor model ranks NeurAxis, Inc. 47 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NRXS stock forecast for 2030?

No analyst covering NeurAxis, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NRXS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $13 over the next 12 months.

How has NRXS stock performed over the past year?

NeurAxis, Inc. returned +68.1% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does NeurAxis, Inc. do?

NeurAxis, Inc. is a medical technology company focused on neuromodulation therapies for chronic and debilitating conditions, with an emphasis on disorders of the gut-brain interaction. Its current product portfolio centers on IB-Stim, a drug-free, non-surgical device worn behind the ear and designed to deliver percutaneous electrical nerve field stimulation for patients with functional abdominal pain associated with irritable bowel syndrome, functional dyspepsia, and related nausea symptoms.

Company

About NeurAxis, Inc.

NeurAxis, Inc. is a medical technology company focused on neuromodulation therapies for chronic and debilitating conditions, with an emphasis on disorders of the gut-brain interaction. Its current product portfolio centers on IB-Stim, a drug-free, non-surgical device worn behind the ear and designed to deliver percutaneous electrical nerve field stimulation for patients with functional abdominal pain associated with irritable bowel syndrome, functional dyspepsia, and related nausea symptoms. The company serves pediatric and adult patients through healthcare settings such as hospitals and clinics, where its therapies are used to support symptom management in targeted gastrointestinal conditions. NeurAxis also works to commercialize evidence-based devices that address unmet needs in digestive health and related neuromodulation care. Headquartered in Carmel, Indiana, NeurAxis operates as a specialized player in the medical device market with a focus on non-invasive treatment options.

CEO Mr. Brian Carrico · 24 employees · United States · https://neuraxis.com